Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2025-02-21 Report Publication Anno…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
EQS-Adhoc: BB Biotech AG publishes its 2024 annual report
Report Publication Announcement Classification · 100% confidence The document is an 'Ad hoc announcement' dated February 21, 2025, explicitly stating: 'BB Biotech AG publishes its 2024 annual report'. It provides a brief summary of the 2024 performance (NAV, net profit) and then directs the reader to a link where the full annual report is available ('BB Biotech’s annual report 2024 is available under [link]'). According to Rule #2 (The 'MENU VS MEAL' Rule), when a document is short and announces the publication of a full report (like the Annual Report), it should be classified as a Report Publication Announcement (RPA), not the report itself (10-K).
2025-02-21 English
EQS-Adhoc: BB Biotech AG veröffentlicht Geschäftsbericht 2024
Report Publication Announcement Classification · 99% confidence The document is an 'Ad hoc-Mitteilung' (Ad hoc announcement) dated February 21, 2025, explicitly stating that 'BB Biotech AG veröffentlicht Geschäftsbericht 2024' (BB Biotech AG publishes Annual Report 2024). It summarizes key financial results (Net Profit, NAV change, dividend proposal) and then directs the reader to external links where the 'vollständige Geschäftsbericht 2024' (complete Annual Report 2024) is available. Since the document itself is short (3972 characters) and primarily serves to announce the publication and provide a link to the full report, it fits the definition of a Report Publication Announcement (RPA) based on the 'MENU VS MEAL' rule. It is not the full Annual Report (10-K) itself.
2025-02-21 German
EQS-News: Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics
Report Publication Announcement Classification · 95% confidence The document is a media release announcing the publication of the 'Annual Report 2024' for BB Biotech AG. It provides a summary of financial highlights, performance metrics, and strategic outlook, but explicitly concludes with a link to the full report, indicating it is an announcement rather than the full 10-K/Annual Report itself. Per the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement. FY 2024
2025-02-21 English
EQS-News: Geschäftsbericht 2024: BB Biotech positioniert sich in einem herausfordernden Markt mit ersten Erholungstendenzen
Earnings Release Classification · 100% confidence The document is titled 'Geschäftsbericht 2024' (Annual Report 2024) and contains comprehensive financial performance data for the full year 2024 and Q4 2024, including Reingewinn/-verlust (Net Profit/Loss), NAV performance, and detailed commentary on strategy, portfolio changes, and management updates. The presence of full-year financial results, performance tables comparing the current year to the previous year, and the explicit title 'Geschäftsbericht' strongly indicates this is the company's official annual report. Although it is presented as a news release (EQS-News), the content itself is the substance of the annual report, not merely an announcement of its publication (which would be RPA or RNS). Therefore, it aligns best with the Annual Report category. FY 2024
2025-02-21 German
Annual financial report 2024
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2024' and contains comprehensive financial statements, including a consolidated balance sheet, statement of comprehensive income, cash flow, and notes to the financial statements. It also includes sections on corporate governance, remuneration, and ESG, which are standard components of a full annual report. It is not an announcement of a report, but the report itself. FY 2024
2025-02-21 English
BB Biotech: Preliminary full-year 2024 results and dividend proposal
Earnings Release Classification · 100% confidence The document is titled "BB Biotech: Preliminary full-year 2024 results and dividend proposal" and contains key financial highlights (Net profit/loss, NAV performance, share price return) for the full year 2024 and Q4 2024. It explicitly states these figures are 'preliminary and unaudited'. It also announces a dividend proposal for the upcoming AGM. This structure—a brief announcement of key financial metrics for a period, often preceding the full audited report—is characteristic of an Earnings Release (ER). Although it mentions the full Annual Report will be published later (February 21, 2025), this document itself is the initial release of the results. It is too detailed for just a Report Publication Announcement (RPA) and contains more than just dividend information (DIV) or NAV updates (NAV). FY 2024
2025-01-25 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.